



# MINIMUM AND OPTIMAL REQUIREMENTS FOR NPHRL

### SURVEY RESULTS ON CAPACITY FOR TESTING AND SURVEILLANCE OF AMR

Egle Kudirkiene

Network meeting 2021 November 30 – December 1








- All Member States (MS) are obliged to collect relevant and comparable data on Salmonella and Campylobacter:
  - infections in humans,
  - food-related outbreaks, and
  - the occurrence of resistance to antimicrobials (AMR) relevant for the treatment of human infections with these bacteria
- The data must be reported to ECDC, however the it is not always comparable due to:
  - dissimilar organisation and operation of the national public health reference laboratories (NPHRLs) in different MSs
  - variation in data quality level
  - differences in the case definitions and methodologies used


# **CORE FUNCTIONS OF NPHRL**





une 2010

# MONITORING OF NPHRL MICROBIOLOGY SYSTEM



#### Substantial variation in capacities and capabilities between the laboratories

Some laboratories:

- Had an insufficient level of laboratory capacity and capability to conduct effective public health surveillance

- Were unable to provide an adequate level of disease threat response

RECOMMENDATIONS OF MINIMUM AND OPTIMALATENS REQUIREMENTS OF THE REFERENCE LEVEL INSTITUT FUNCTIONS FOR THE NATIONAL SURVEILLANCE SYSTEMS FOR AMR IN SALMONELLA AND CAMPYLOBACTER IN HUMANS

#### 1. Support to primary diagnostic testing

#### 2. Laboratory-based surveillance of AMR, alert and response

- Support to national surveillance networks
- National outbreak response support
- Participation in EU disease networks and research
- The design of AMR surveillance system, sampling and testing frequency
- Referral, timing and storage of Salmonella and Campylobacter isolates

#### 3. National Public Health Reference Laboratory Services

- Internal and external quality control
- Reference diagnostics and characterisation of Salmonella
- Reference diagnostics and characterisation of Campylobacter

# MINIMAL VS. OPTIMAL REQUIREMENTS



- In the same laboratory, both minimum and optimal requirements may be applied, e.g.
  - minimum requirements for the majority of clinical samples/isolates
  - optimal requirements on a subset of samples/isolates

- If, NPHRLs do not have the capacity and capability to operate according to at least minimum requirements
  - service level agreement(s) with other expert or reference level
    laboratories should be in place



#### Salmonella

Requirements	Serotyping	Antimicrobial resistance	Cluster detection
Minimum	Phenotypic or genotypic: common serovars	Phenotypic AST or genotypic AMR prediction	High resolution molecular typing (e.g. MLVA)
Optimal	Phenotypic or genotypic: all serovars	Phenotypic AST and WGS-based AMR prediction*	WGS-based (e.g. cgMLST, wgMLST, SNP)

#### Campylobacter

Requirements	Species	Antimicrobial resistance	Cluster detection
Minimum	Phenotypic or genotypic: <i>C. jejuni,</i> <i>C. coli</i>	Phenotypic AST or genotypic AMR prediction	Not applicable**
Optimal	Phenotypic or genotypic: all species	Phenotypic AST and WGS-based AMR prediction*	WGS-based (e.g., cgMLST, wgMLST, SNP)

\* a defined proportion of isolates or selected isolates are periodically tested phenotypically to ensure detection of novel resistance mechanisms

\*\* Some laboratories may use Pulsed-field gel electrophoresis (PFGE) for cluster detection but this is not considered as a minimum requirement

# THE FOCUS OF THE SURVEY



- to identify capacity and capability gaps in technical and analytical skills of AMR testing and strain subtyping at national level in all countries
- identify countries with the greatest needs for capacity building in phenotypic and genomic testing of AMR ('priority countries')
  - provide tailored technical and operational support for implementation of phenotypic and genomic testing of AMR in human Salmonella and Campylobacter
  - provide direct advice and support for each country to create an action plan to strengthen its national reference laboratory capacities in line with standards set out in EULabCap documentation
- identify 'additional countries' facing challenges to identify and manage outbreaks of Salmonella spp. and Campylobacter spp.

# SURVEY OUTCOME

- Sent to 37 countries (32 EU/EEA/EU Health programme countries and 5 EU-candidate countries)
- Responses received from 31 EU/EEA/EU Health programme countries and all 5 EU-candidate countries (n=36)
  - In 29/36 countries responses from the same laboratory covering both Salmonella and Campylobacter were received
  - In 6/36 countries responses from two laboratories covering either Salmonella or Campylobacter were received
  - One country responded for Salmonella spp. only






# SALMONELLA

- AMR testing overview
- Data and sample collection for surveillance of AMR
- National AMR surveillance system coverage
- Molecular subtyping of Salmonella isolates

# AMR TESTING OVERVIEW - SALMONELLA

The purpose and the number of antimicrobials tested (phenotypic and genotypic)

14






STATENS SERUM INSTITUT

# DATA FOR AMR SURVEILLANCE - SALMONELLA

#### Collection of laboratory data





### 76-100 26-50 51-75 submitting laboratory data and/or sample material 76-100 % of the local/regional clinical laboratories 8 2 3 for national surveillance of AMR 51-75 26-50 0-25 Unknown

# % of the total number of *Salmonella* enteritis cases tested for AMR annually

0-25


Unknown



MOLECULAR SUBTYPING OF SALMONELLA ISOLATE




#### **Objectives of molecular subtyping**



# SALMONELLA AMR SURVEILLANCE IN NON-EU COUNTRIES








# CAMPYLOBACTER

- AMR testing overview
- Data and sample collection for surveillance of AMR
- National AMR surveillance system coverage
- Molecular subtyping of *Campylobacter* isolates

# AMR TESTING OVERVIEW - CAMPYLOBACTER


28

#### The purpose and the number of antimicrobials tested in all laboratories






#### Collection of laboratory data








MOLECULAR SUBTYPING OF CAMPYLOBACTER ISOLATES




#### **Objectives of molecular subtyping**






#### EU/EEA/EU Health

#### AMR testing on outbreak isolates



## CAMPYLOBACTER AMR SURVEILLANCE IN NON-ELINS COUNTRIES






# SUMMARY



- Nearly all NPHRLs have a capacity to perform testing of AMR in Salmonella and Campylobacter isolates from humans using either phenotypic of genotypic methods, however:
  - Approx. 2/3 of NPHRLs perform AMR surveillance and strain subtyping of *Salmonella* isolates
  - Approx. 1/3 of NPHRLs perform AMR surveillance and strain subtyping of Campylobacter isolates



# ACKNOWLEDGEMENTS



#### • Team members at SSI

- Eva Møller Nielsen
- Susanne Schjørring
- Malgorzata Ligowska-Marzeta
- Jeppe Boel
- etc.



- EURGen-RefLabCap team at SSI:
  - Valeria Bortolaia
  - Camilla Wiuff Coia

# Everyone who responded to the survey!